Literature DB >> 9354676

A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.

R Richelda1, D Ronchetti, L Baldini, L Cro, L Viggiano, R Marzella, M Rocchi, T Otsuki, L Lombardi, A T Maiolo, A Neri.   

Abstract

Chromosomal translocations involving the immunoglobulin heavy chain (IGH) locus at chromosome 14q32 represent a common mechanism of oncogene activation in lymphoid malignancies. In multiple myeloma (MM), the most consistent chromosomal abnormality is the 14q+ marker, which originates in one third of cases through a t(11; 14)(q13; q32) chromosomal translocation; in the remaining cases, the identity of the partner chromosomes has not been well established. We used a Southern blot approach based on the linkage analysis of the joining (J) and the constant (C) mu, alpha, and gamma regions to detect cases bearing IGH switch-mediated chromosomal translocations. We evaluated DNA of 88 nonkaryotyped patients with MM (78 cases) or plasma cell leukemia (PCL) (10 cases) and found the presence of "illegitimate" rearranged IGH fragments (no comigration between the J and C regions) in 21 cases. To confirm this analysis, we cloned the illegitimate rearranged fragments from three samples, and the molecular and fluorescent in situ hybridization (FISH) analyses indicated the presence of chromosomal translocations juxtaposing a switch IGH region to sequences from chromosomes 11q13 (one PCL case) or 4p16.3 (two MM cases). Interestingly, the breakpoints on 4p16.3 occurred about 14 kb apart in a genomic region located approximately 50 kb centromeric to the fibroblast growth-factor receptor 3 (FGFR3) gene. Moreover, Southern blot analysis using 4p16.3 genomic probes detected a rearrangement in an additional MM tumor. FISH analysis of the MM-derived KMS-11 cell line, reported to be associated with a t(4; 14)(p16.3; q32), showed that the FGFR3 gene was translocated on 14q32. High levels of FGFR3 mRNA expression were observed in the cloned MM tumors and KMS-11 cell line, but not in the cases that were apparently negative for this lesion. Furthermore, a point mutation at codon 373 in the transmembrane domain of the FGFR3 gene resulting in an amino acid substitution (Tyr --> Cys) was detected in the KMS-11 cell line. These findings indicate that the t(4; 14)(p16.3; q32) represents a novel, recurrent chromosomal translocation in MM, and suggest that the FGFR3 gene may be the target of this abnormality and thus contribute to tumorigenesis in MM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354676

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.

Authors:  Jian Ren; Deepak Raina; Wen Chen; Guilan Li; Lei Huang; Donald Kufe
Journal:  Mol Cancer Res       Date:  2006-11       Impact factor: 5.852

Review 2.  Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.

Authors:  Edwin Li; Kalina Hristova
Journal:  Biochemistry       Date:  2006-05-23       Impact factor: 3.162

3.  Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.

Authors:  April N Meyer; Christopher W McAndrew; Daniel J Donoghue
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

4.  A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.

Authors:  Huaibin Chen; Jinghong Ma; Wanqing Li; Anna V Eliseenkova; Chongfeng Xu; Thomas A Neubert; W Todd Miller; Moosa Mohammadi
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

5.  Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Authors:  Elie Traer; Nathalie Javidi-Sharifi; Anupriya Agarwal; Jennifer Dunlap; Isabel English; Jacqueline Martinez; Jeffrey W Tyner; Melissa Wong; Brian J Druker
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

6.  Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.

Authors:  Yujia Wang; Lushuang Xu; Yang Liu; Yuzhe Hu; Qiang Shi; Lixue Jin; Lijun Yang; Pingzhang Wang; Kunshan Zhang; Xiaojun Huang; Qing Ge; Jin Lu
Journal:  Int J Hematol       Date:  2020-10-10       Impact factor: 2.490

7.  MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.

Authors:  Jose L R Brito; Brian Walker; Matthew Jenner; Nicholas J Dickens; Nicola J M Brown; Fiona M Ross; Athanasia Avramidou; Julie A E Irving; David Gonzalez; Faith E Davies; Gareth J Morgan
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

8.  A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.

Authors:  Lisa Salazar; Tamara Kashiwada; Pavel Krejci; Paul Muchowski; Daniel Donoghue; William R Wilcox; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

9.  CSNK1α1 mediates malignant plasma cell survival.

Authors:  Y Hu; W Song; D Cirstea; D Lu; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2014-06-25       Impact factor: 11.528

10.  The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects.

Authors:  Sara Ota; Zi-Qiang Zhou; Jason M Link; Peter J Hurlin
Journal:  Hum Mol Genet       Date:  2009-04-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.